Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| BRCA2 Protein | 5 | 2020 | 37 | 1.910 |
Why?
|
| Breast Neoplasms | 15 | 2022 | 1502 | 1.740 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2023 | 628 | 1.320 |
Why?
|
| BRCA1 Protein | 4 | 2020 | 48 | 1.290 |
Why?
|
| Genetic Variation | 3 | 2019 | 387 | 1.150 |
Why?
|
| Genetic Testing | 5 | 2023 | 75 | 0.850 |
Why?
|
| DNA Repair | 5 | 2021 | 188 | 0.800 |
Why?
|
| Quantitative Trait Loci | 7 | 2005 | 77 | 0.740 |
Why?
|
| Oncogenes | 1 | 2019 | 43 | 0.700 |
Why?
|
| Blood Pressure | 10 | 2005 | 646 | 0.700 |
Why?
|
| Population Groups | 1 | 2019 | 56 | 0.660 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 5 | 0.630 |
Why?
|
| Neoplasms | 4 | 2023 | 1103 | 0.620 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2021 | 767 | 0.540 |
Why?
|
| Mutation | 8 | 2021 | 1095 | 0.530 |
Why?
|
| Puerto Rico | 12 | 2022 | 1378 | 0.520 |
Why?
|
| Models, Biological | 1 | 2019 | 677 | 0.520 |
Why?
|
| DNA-Binding Proteins | 3 | 2019 | 539 | 0.520 |
Why?
|
| Ovarian Neoplasms | 4 | 2022 | 312 | 0.490 |
Why?
|
| Chromosome Mapping | 12 | 2021 | 188 | 0.480 |
Why?
|
| Rats, Inbred Dahl | 9 | 2005 | 33 | 0.460 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2013 | 4 | 0.460 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 20 | 0.450 |
Why?
|
| Genetics, Population | 4 | 2021 | 100 | 0.450 |
Why?
|
| Humans | 35 | 2023 | 37093 | 0.390 |
Why?
|
| Child Day Care Centers | 1 | 2011 | 11 | 0.390 |
Why?
|
| Education | 1 | 2011 | 55 | 0.380 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1130 | 0.350 |
Why?
|
| Child Abuse | 1 | 2011 | 79 | 0.350 |
Why?
|
| Female | 25 | 2022 | 20969 | 0.350 |
Why?
|
| Chromosomes | 4 | 2005 | 37 | 0.330 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 219 | 0.330 |
Why?
|
| DNA Methylation | 2 | 2021 | 325 | 0.310 |
Why?
|
| Alleles | 3 | 2021 | 321 | 0.270 |
Why?
|
| Hypertension | 4 | 2005 | 796 | 0.270 |
Why?
|
| Latin America | 4 | 2022 | 45 | 0.260 |
Why?
|
| Gene Frequency | 3 | 2015 | 195 | 0.260 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2005 | 23 | 0.260 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 130 | 0.230 |
Why?
|
| Genetic Markers | 8 | 2012 | 142 | 0.220 |
Why?
|
| Middle Aged | 12 | 2022 | 10129 | 0.210 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 49 | 0.210 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 935 | 0.210 |
Why?
|
| Multiple Myeloma | 1 | 2022 | 39 | 0.210 |
Why?
|
| DNA, Neoplasm | 1 | 2021 | 92 | 0.200 |
Why?
|
| Biological Clocks | 1 | 2021 | 53 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 39 | 0.190 |
Why?
|
| Receptor, Melanocortin, Type 1 | 1 | 2020 | 3 | 0.180 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 275 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 132 | 0.180 |
Why?
|
| Animals, Congenic | 9 | 2005 | 11 | 0.180 |
Why?
|
| Skin Pigmentation | 1 | 2020 | 23 | 0.180 |
Why?
|
| Genetic Counseling | 4 | 2022 | 11 | 0.180 |
Why?
|
| DNA Glycosylases | 1 | 2019 | 16 | 0.180 |
Why?
|
| Quantitative Trait, Heritable | 4 | 2005 | 26 | 0.180 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 156 | 0.180 |
Why?
|
| Point Mutation | 1 | 2019 | 93 | 0.170 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 57 | 0.170 |
Why?
|
| Mutation, Missense | 1 | 2019 | 83 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 807 | 0.170 |
Why?
|
| Molecular Epidemiology | 1 | 2019 | 50 | 0.170 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 191 | 0.170 |
Why?
|
| Prognosis | 3 | 2020 | 739 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 159 | 0.160 |
Why?
|
| Introns | 1 | 2018 | 75 | 0.150 |
Why?
|
| Adenoma | 1 | 2018 | 89 | 0.150 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2016 | 8 | 0.150 |
Why?
|
| Aged | 8 | 2021 | 6741 | 0.140 |
Why?
|
| Rats | 10 | 2005 | 3483 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2021 | 854 | 0.140 |
Why?
|
| Chromosomes, Mammalian | 3 | 2005 | 18 | 0.140 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 186 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2018 | 251 | 0.140 |
Why?
|
| Models, Molecular | 1 | 2019 | 808 | 0.140 |
Why?
|
| Quality of Life | 1 | 2020 | 481 | 0.130 |
Why?
|
| Male | 14 | 2021 | 20025 | 0.130 |
Why?
|
| Caribbean Region | 1 | 2015 | 69 | 0.130 |
Why?
|
| United States | 4 | 2022 | 4223 | 0.130 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 560 | 0.130 |
Why?
|
| Minority Groups | 1 | 2020 | 596 | 0.130 |
Why?
|
| Stress, Psychological | 1 | 2020 | 583 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2018 | 2026 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2020 | 642 | 0.120 |
Why?
|
| Genotype | 2 | 2013 | 730 | 0.120 |
Why?
|
| Risk Factors | 4 | 2017 | 3562 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 358 | 0.110 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 2231 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2012 | 753 | 0.100 |
Why?
|
| Heterozygote | 1 | 2012 | 93 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 448 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 494 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2012 | 100 | 0.100 |
Why?
|
| Complement C3 | 1 | 2011 | 16 | 0.100 |
Why?
|
| Infertility, Female | 1 | 2011 | 24 | 0.100 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2011 | 35 | 0.100 |
Why?
|
| Indians, North American | 1 | 2013 | 159 | 0.100 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 29 | 0.100 |
Why?
|
| CpG Islands | 2 | 2021 | 97 | 0.100 |
Why?
|
| Insurance, Health | 1 | 2012 | 126 | 0.100 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 45 | 0.100 |
Why?
|
| Patient Selection | 1 | 2012 | 164 | 0.090 |
Why?
|
| Logistic Models | 3 | 2022 | 923 | 0.090 |
Why?
|
| Survivors | 2 | 2022 | 136 | 0.090 |
Why?
|
| DNA Damage | 1 | 2012 | 352 | 0.090 |
Why?
|
| Endometriosis | 1 | 2011 | 73 | 0.090 |
Why?
|
| Rats, Inbred Lew | 6 | 2005 | 21 | 0.090 |
Why?
|
| Phenotype | 3 | 2021 | 689 | 0.090 |
Why?
|
| Receptors, Progesterone | 2 | 2022 | 81 | 0.080 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 626 | 0.080 |
Why?
|
| Child | 2 | 2021 | 3131 | 0.080 |
Why?
|
| Pilot Projects | 2 | 2021 | 661 | 0.080 |
Why?
|
| Receptor, erbB-2 | 2 | 2022 | 133 | 0.080 |
Why?
|
| Animals | 10 | 2005 | 15081 | 0.080 |
Why?
|
| Biomedical Research | 1 | 2012 | 400 | 0.070 |
Why?
|
| Mexico | 2 | 2021 | 240 | 0.070 |
Why?
|
| Young Adult | 4 | 2021 | 4268 | 0.070 |
Why?
|
| Aorta | 2 | 2005 | 167 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 974 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2020 | 1378 | 0.070 |
Why?
|
| Adult | 6 | 2020 | 11712 | 0.070 |
Why?
|
| Health Promotion | 1 | 2011 | 653 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 212 | 0.060 |
Why?
|
| DNA Primers | 1 | 2005 | 286 | 0.060 |
Why?
|
| Epistasis, Genetic | 1 | 2003 | 16 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 2379 | 0.060 |
Why?
|
| Base Sequence | 1 | 2005 | 997 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2022 | 18 | 0.050 |
Why?
|
| Peru | 1 | 2022 | 30 | 0.050 |
Why?
|
| Language | 1 | 2023 | 157 | 0.050 |
Why?
|
| Internet | 1 | 2023 | 211 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 73 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 64 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 49 | 0.050 |
Why?
|
| Florida | 1 | 2022 | 410 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2020 | 105 | 0.050 |
Why?
|
| Genomics | 1 | 2021 | 223 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 239 | 0.040 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2018 | 31 | 0.040 |
Why?
|
| Mucous Membrane | 1 | 2018 | 34 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 601 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2018 | 25 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2018 | 43 | 0.040 |
Why?
|
| Prevalence | 1 | 2022 | 1455 | 0.040 |
Why?
|
| Sex Factors | 1 | 2021 | 898 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 885 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2019 | 333 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2021 | 1418 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2017 | 455 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2721 | 0.030 |
Why?
|
| Human Genome Project | 1 | 2013 | 7 | 0.030 |
Why?
|
| Genome | 2 | 2005 | 125 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2016 | 336 | 0.030 |
Why?
|
| Genome, Human | 1 | 2013 | 135 | 0.030 |
Why?
|
| Argentina | 1 | 2012 | 12 | 0.030 |
Why?
|
| ROC Curve | 1 | 2012 | 138 | 0.030 |
Why?
|
| Mexican Americans | 1 | 2013 | 189 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2011 | 85 | 0.020 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 2011 | 67 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 562 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 225 | 0.020 |
Why?
|
| Culture | 1 | 2012 | 173 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 534 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 935 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2005 | 90 | 0.020 |
Why?
|
| Lod Score | 1 | 2005 | 9 | 0.020 |
Why?
|
| Homozygote | 1 | 2005 | 77 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2005 | 172 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2004 | 27 | 0.010 |
Why?
|
| Breeding | 1 | 2003 | 21 | 0.010 |
Why?
|
| Telemetry | 1 | 2003 | 14 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2005 | 180 | 0.010 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2003 | 31 | 0.010 |
Why?
|
| Mice | 2 | 2005 | 5913 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 115 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 306 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 128 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 157 | 0.010 |
Why?
|
| Cardiomegaly | 1 | 2002 | 41 | 0.010 |
Why?
|
| Models, Animal | 1 | 2002 | 134 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 400 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 434 | 0.010 |
Why?
|
| Kidney | 1 | 2002 | 337 | 0.010 |
Why?
|